香港股市 已收市

Roche Holding AG (RHHVF)

Other OTC - Other OTC 延遲價格。貨幣為 USD。
加入追蹤清單
302.77+1.43 (+0.48%)
收市價: 03:32PM EST
全螢幕
交易股價資料並非來自所有市場
前收市價301.33
開市302.00
買盤0.00 x 0
賣出價0.00 x 0
今日波幅302.00 - 306.83
52 週波幅298.00 - 430.00
成交量23,200
平均成交量6,596
市值245.728B
Beta 值 (5 年,每月)0.21
市盈率 (最近 12 個月)16.14
每股盈利 (最近 12 個月)18.76
業績公佈日
遠期股息及收益率9.97 (3.24%)
除息日2022年3月17日
1 年預測目標價423.65
  • Benzinga

    Roche Flags Lower 2023 Sales On Declining Demand For COVID-19 Treatment, Diagnostics

    Roche Holdings AG (OTC: RHHBY) released FY22 sales growth of 2% (+1% in CHF) to CHF 63.3 billion. Core operating profit increased by 3% (+1% in CHF), reflecting the good underlying business performance. The company warned that in 2023, a sharp decline in COVID-19 products would knock sales by around CHF 5 billion. Sales and core earnings per share were expected to decrease at a "low single-digit" percentage this year, the company said. Related: FDA Approves Roche's Tocilizumab As First Monoclona

  • Benzinga

    Roche Introduces Test To Detect Contagious XBB.1.5 Omicron Sub-Variant

    Roche Holding Ltd (OTC: RHHBF) (OTC: RHHBY) and its subsidiary TIB Molbiol have developed a COVID-19 PCR test for researchers that detects and differentiates the latest variant of concern, XBB.1.5. The XBB.1.5 Omicron sub-variant is prevalent in the U.S. and quickly spreads to other countries. Being able to differentiate emerging variants and understand their similarities and mutations provides a basis for experts to make predictions about their spread and respond with appropriate treatment stra

  • Benzinga

    Genentech's Tecentriq Plus Avastin Combo Cuts Risk of Cancer Returning In Early-Stage Liver Cancer

    Genentech, a unit of Roche Holdings AG (OTC: RHHBY), announced that the Phase 3 IMbrave050 study met its primary endpoint of recurrence-free survival (RFS) at the prespecified interim analysis. The study evaluates Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as adjuvant treatment following surgery for people with early-stage hepatocellular carcinoma (HCC) at high risk of disease recurrence. The Tecentriq combination showed a statistically significant improvement in RFS in t